Wilson Sonsini Advises Replay on IP Strategy Related to Launch, $55 Million Seed Funding
- Client Highlights
- Life Sciences
On July 25, 2022, Replay, a genome writing company reprogramming biology by writing and delivering big DNA, announced its launch with $55 million in seed financing. The round was led by KKR and OMX Ventures, with additional participation from ARTIS Ventures and Lansdowne Partners, SALT, DeciBio Ventures, and Axial. Wilson Sonsini Goodrich & Rosati has been a long-term adviser to Replay on its IP strategy.
Replay’s portfolio of next-generation genomic medicine technologies aims to solve the key challenges currently limiting clinical progress, including the need for increased payload capacity and off-the-shelf cell therapies that substantially reduce cost of goods, improve production speed, volume, and consistency, and expand the potential for genome engineering.
In addition to a genomic medicine toolkit that comprises several synergistic technology platforms, Replay has an innovative corporate structure that separates technology development from therapeutic product development within disease area-specific product companies. To date, Replay has established four synHSV™ gene therapy product companies, aimed at bringing big DNA therapies to monogenic diseases affecting the skin, eye, brain, and muscle, and an enzyme writing product company using LASR™ and DropSynth™ to optimize enzyme functionality.
The Wilson Sonsini team that advised Replay on IP strategy includes Ali Alemozafar, Maysam Pessian, Vishakha Negi, and Matt Adrianowycz.
According to Adrian Woolfson, executive chairman, president, and co-founder of Replay, “The intellectual property team at Wilson Sonsini Goodrich & Rosati, led by Ali Alemozafar and with the support of Maysam Pessian, have been trusted advisers to Replay since the time of its incorporation and have helped facilitate the IP strategy and multi-faceted IP portfolio that sustains our hub-and-spoke business model.”
Added Lachlan MacKinnon, CEO and co-founder of Replay, “Wilson Sonsini Goodrich & Rosati has played a steadfast role in helping the company to build its IP portfolio.”
For more information, please see Replay Bio's press release.